NCT04204057 2024-08-13Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Rhizen Pharmaceuticals SAPhase 2 Completed21 enrolled 12 charts